New combo therapy targets Hard-to-Treat sarcoma
NCT ID NCT07460986
First seen Mar 10, 2026 · Last updated May 12, 2026 · Updated 11 times
Summary
This study tests a new drug called bexmarilimab (an antibody) combined with the chemotherapy doxorubicin in people with metastatic soft-tissue sarcoma (a type of cancer that has spread). The goal is to find the safest dose and see if the combination helps control tumor growth. About 278 adults whose cancer has not responded to prior treatments will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARCOMA OF SOFT TISSUE are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.